D. Brousseau, J. Panepinto, M. Nimmer, and R. Hoffmann, The number of people with sickle cell disease in the United States: National and state estimates, American Journal of Hematology, vol.85, pp.77-85, 2010.
DOI : 10.1002/ajh.21570

B. Modell and M. Darlison, Global epidemiology of haemoglobin disorders and derived service indicators, Bulletin of the World Health Organization, vol.2008, issue.6, pp.480-487, 2008.
DOI : 10.2471/BLT.06.036673

V. Ingram, A Specific Chemical Difference Between the Globins of Normal Human and Sickle-Cell An??mia H??moglobin, Nature, vol.110, issue.4537, pp.792-796, 1956.
DOI : 10.1042/bj0590653

J. Strouse, S. Lanzkron, and M. Beach, Hydroxyurea for Sickle Cell Disease: A Systematic Review for Efficacy and Toxicity in Children, PEDIATRICS, vol.122, issue.6, pp.1332-1374, 2008.
DOI : 10.1542/peds.2008-0441

F. Bernaudin, G. Socie, and M. Kuentz, Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease, Blood, vol.110, issue.7, pp.2749-56, 2007.
DOI : 10.1182/blood-2007-03-079665

M. Bhatia and M. Walters, Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future, Bone Marrow Transplantation, vol.12, issue.2
DOI : 10.1111/j.1365-2141.2006.06486.x

URL : http://www.nature.com/bmt/journal/v41/n2/pdf/1705943a.pdf

, Bone Marrow Transplant, vol.41, pp.109-126, 2008.

L. Krishnamurti, S. Abel, M. Maiers, and S. Flesch, Availability of unrelated donors for hematopoietic stem cell transplantation for hemoglobinopathies, Bone Marrow Transplantation, vol.91, issue.7, pp.547-50, 2003.
DOI : 10.1002/1097-0142(20010101)91:1+<274::AID-CNCR18>3.0.CO;2-E

W. Mentzer, S. Heller, P. Pearle, E. Hackney, and E. Vichinsky, Availability of related donors for bone marrow transplantation in sickle cell anemia, Am J Pediatr Hematol Oncol, vol.16, pp.27-36, 1994.

P. Malik and P. Leboulch, Genetically engineered cures: gene therapy for sickle cell disease Renaissance of sickle cell disease research in the genome era, pp.295-310, 2007.

K. Takekoshi, Y. Oh, K. Westerman, I. London, P. Leboulch et al., Retroviral transfer of a human beta-globin/delta-globin hybrid gene linked to beta locus control region hypersensitive site 2 aimed at the gene therapy of sickle cell disease., Proceedings of the National Academy of Sciences, vol.92, issue.7, pp.3014-3022, 1995.
DOI : 10.1073/pnas.92.7.3014

O. Negre, C. Bartholomae, and Y. Beuzard, Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of &#946;-Thalassemia and Sickle Cell Disease, Current Gene Therapy, vol.15, issue.1, pp.64-81, 2015.
DOI : 10.2174/1566523214666141127095336

E. Montini, D. Cesana, and M. Schmidt, The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy, Journal of Clinical Investigation, vol.119, issue.4, pp.964-75, 2008.
DOI : 10.1172/JCI37630DS1

S. Howe, M. Mansour, and K. Schwarzwaelder, Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients, Journal of Clinical Investigation, vol.118, issue.9, pp.3143-50, 2008.
DOI : 10.1172/JCI35798DS1

X. Wu, Y. Li, B. Crise, S. Burgess, J. Kwiatkowski et al., Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration, Science, vol.300, issue.5626, pp.1749-51204, 2003.
DOI : 10.1126/science.1083413

M. Walters and M. Hsieh, Interim results from a phase 1/2 clinical study of LentiGlobin gene therapy for severe sickle cell disease Sickle cell disease in Saudi Arabia: the phenotype in adults with the Arab-Indian haplotype is not benign Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia Outcomes of gene therapy for severe sickle disease and beta-thalassemia major via transplantation of autologous hematopoietic stem cells transduced ex vivo with a lentiviral beta AT87Q-globin vector Update of results from the Northstar Study (HGB-204): a phase 1/2 study of gene therapy for beta-thalassemia major via transplantation of autologous hematopoietic stem cells transduced ex-vivo with a lentiviral beta AT87Q-globin vector (LentiGlobin BB305 drug product), Phase 1/2 Clinical Study. Presented at the 58th Annual Meeting of the Presented at the 58th Annual Meeting of the al. Transfusion independence and HMGA2 activation after gene therapy of human ?-thalassaemia, pp.597-604, 2001.

, Copyright © 2017 Massachusetts Medical Society

, For personal use only. No other uses without permission, 2017.